# AtriCure Inc. (ATRC) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Health Care Equipment & Supplies. Price $51.52, market value $2.6 billion.

## Valuation
- **P/E (trailing): 245.3×** (5-yr avg 63.8×). AtriCure Inc. trades at 245.3× trailing earnings, well above its own five-year average of 63.8×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 119.3×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 1.60**. A PEG of 1.60 is in the range usually read as fairly priced for its growth.
- **Price / sales: 4.6×**. Each dollar of revenue is priced at 4.6×.
- **Price / book: 5.1×**. The shares trade at 5.1× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: 2.0%** (5-yr avg -0.1%). Free cash flow equals 2.0% of the market value, above its five-year average of -0.1%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 0.4%**. The inverse of the P/E: 0.4% of the price is earned each year.

## Profitability
- **Gross margin: 76.3%**. AtriCure Inc. keeps 76.3% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 2.3%**. 2.3% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: -2.1%**. The company reported a net loss over the last twelve months.
- **Return on equity: -2.3%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 2.6%**. Return on all capital, debt included, is 2.6%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 1.6%**. Each dollar of assets produces 1.6% of profit.

## Growth
- **Revenue growth (1 yr): 14.9%** (3-yr 17.4%/yr, 5-yr 20.9%/yr). Revenue grew 14.9% over the last year, against 20.9% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 74.7%**. Earnings per share rose 74.7%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.13**. Debt is 0.13 times equity: a conservative balance sheet.
- **Altman Z-score: 11.51**. A Z-score of 11.51 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. AtriCure Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (9 analysts). 9 analysts cover AtriCure Inc.; the consensus is buy, with an average price target of $49.56 (-4% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 44.5%** (YTD 30.2%, 3-mo 90.1%). The shares are up 44.5% over twelve months including dividends.
- **From 52-week high: -3.7%** (103.2% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 74**. An RSI of 74 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 0.61** (volatility 47%). Beta of 0.61 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ATRC · Page: https://foliofundamentals.com/stocks/atrc

Not investment advice.